The Application of Patient-derived Organoid in the Research of Lung Cancer

Overview

Journal Cell Oncol (Dordr)

Publisher Springer

Date 2023 Jan 25

PMID 36696006

Authors

Yin Li

Xinyu Gao

Chao Ni

Bing Zhao

Xinghua Cheng

Affiliations

Soon will be listed here.

Abstract

Lung cancer is the most common cancer and the leading cause of cancer-related death worldwide. However, mechanisms of its progression remained unclear and new treatments against this disease are rapidly emerging. As a novel preclinical model, patient-derived organoid (PDO) can also be established from the patient's tumor tissue and cultured in the laboratory, which preserves the key biological characteristics of the original tumor. Compared to the patient-derived xenograft (PDX) model of lung cancer, the culture success rate is improved, and the time and cost of model establishment are largely reduced. PDO is also expected to provide a more individual model to predict the efficacy of anti-cancer treatment in vitro. This paper summarizes the current application of PDO in the translational research of lung cancer.

Citing Articles

Construction methods and latest applications of kidney cancer organoids.

Li Z, You Y, Feng B, Chen J, Gao H, Li F Oncol Rev. 2024; 18:1434981.

PMID: 39600908 PMC: 11588466. DOI: 10.3389/or.2024.1434981.

RBM15 facilitates osimertinib resistance of lung adenocarcinoma through m6A-dependent epigenetic silencing of SPOCK1.

Li H, Li Y, Zheng X, Chen F, Zhang S, Xu S Oncogene. 2024; 44(5):307-321.

PMID: 39528815 PMC: 11779629. DOI: 10.1038/s41388-024-03220-z.

3D cell culture models in research: applications to lung cancer pharmacology.

Vella N, Fenech A, Petroni Magri V Front Pharmacol. 2024; 15:1438067.

PMID: 39376603 PMC: 11456561. DOI: 10.3389/fphar.2024.1438067.

Applied models and molecular characteristics of small cell lung cancer.

Mihalekne Fur G, Nemes K, Mago E, Beno A, Topolcsanyi P, Moldvay J Pathol Oncol Res. 2024; 30:1611743.

PMID: 38711976 PMC: 11070512. DOI: 10.3389/pore.2024.1611743.

Patient-derived tumoroids and proteomic signatures: tools for early drug discovery.

Le H, Deforges J, Cutolo P, Lamarque A, Hua G, Lindner V Front Immunol. 2024; 15:1379613.

PMID: 38698850 PMC: 11063793. DOI: 10.3389/fimmu.2024.1379613.

References

Marshall L, Triunfol M, Seidle T . Patient-Derived Xenograft vs. Organoids: A Preliminary Analysis of Cancer Research Output, Funding and Human Health Impact in 2014-2019. Animals (Basel). 2020; 10(10). PMC: 7593921. DOI: 10.3390/ani10101923. View

Kim S, Kim S, Lim S, Lee J, Choi S, Yang S . Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma. Clin Cancer Res. 2021; 27(15):4397-4409. PMC: 9401503. DOI: 10.1158/1078-0432.CCR-20-5026. View

Herbst R, Morgensztern D, Boshoff C . The biology and management of non-small cell lung cancer. Nature. 2018; 553(7689):446-454. DOI: 10.1038/nature25183. View

Li Z, Yu L, Chen D, Meng Z, Chen W, Huang W . Protocol for generation of lung adenocarcinoma organoids from clinical samples. STAR Protoc. 2021; 2(1):100239. PMC: 7779824. DOI: 10.1016/j.xpro.2020.100239. View

Elbadawy M, Usui T, Mori T, Tsunedomi R, Hazama S, Nabeta R . Establishment of a novel experimental model for muscle-invasive bladder cancer using a dog bladder cancer organoid culture. Cancer Sci. 2019; 110(9):2806-2821. PMC: 6726682. DOI: 10.1111/cas.14118. View

Qu J, Kalyani F, Liu L, Cheng T, Chen L . Tumor organoids: synergistic applications, current challenges, and future prospects in cancer therapy. Cancer Commun (Lond). 2021; 41(12):1331-1353. PMC: 8696219. DOI: 10.1002/cac2.12224. View

Kozlowski M, Crook C, Ku H . Towards organoid culture without Matrigel. Commun Biol. 2021; 4(1):1387. PMC: 8664924. DOI: 10.1038/s42003-021-02910-8. View

Artegiani B, Hendriks D, Beumer J, Kok R, Zheng X, Joore I . Fast and efficient generation of knock-in human organoids using homology-independent CRISPR-Cas9 precision genome editing. Nat Cell Biol. 2020; 22(3):321-331. DOI: 10.1038/s41556-020-0472-5. View

Chen P, Cai L, Huffman K, Yang C, Kim J, Faubert B . Metabolic Diversity in Human Non-Small Cell Lung Cancer Cells. Mol Cell. 2019; 76(5):838-851.e5. PMC: 6898782. DOI: 10.1016/j.molcel.2019.08.028. View

10.

Ding S, Hsu C, Wang Z, Natesh N, Millen R, Negrete M . Patient-derived micro-organospheres enable clinical precision oncology. Cell Stem Cell. 2022; 29(6):905-917.e6. PMC: 9177814. DOI: 10.1016/j.stem.2022.04.006. View

11.

Peng K, Su J, Xie Z, Wang H, Fang M, Li W . Clinical outcomes of EGFR+/METamp+ vs. EGFR+/METamp- untreated patients with advanced non-small cell lung cancer. Thorac Cancer. 2022; 13(11):1619-1630. PMC: 9161327. DOI: 10.1111/1759-7714.14429. View

12.

Han Y, Shi J, Xu Z, Zhang Y, Cao X, Yu J . Identification of solamargine as a cisplatin sensitizer through phenotypical screening in cisplatin-resistant NSCLC organoids. Front Pharmacol. 2022; 13:802168. PMC: 9399411. DOI: 10.3389/fphar.2022.802168. View

13.

Taverna J, Hung C, DeArmond D, Chen M, Lin C, Osmulski P . Single-Cell Proteomic Profiling Identifies Combined AXL and JAK1 Inhibition as a Novel Therapeutic Strategy for Lung Cancer. Cancer Res. 2020; 80(7):1551-1563. PMC: 7127959. DOI: 10.1158/0008-5472.CAN-19-3183. View

14.

Broyde J, Simpson D, Murray D, Paull E, Chu B, Tagore S . Oncoprotein-specific molecular interaction maps (SigMaps) for cancer network analyses. Nat Biotechnol. 2020; 39(2):215-224. PMC: 7878435. DOI: 10.1038/s41587-020-0652-7. View

15.

Yun J, Lee S, Kim S, Jeong S, Kim J, Pyo K . Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of Exon 20 Insertion-Driven NSCLC. Cancer Discov. 2020; 10(8):1194-1209. DOI: 10.1158/2159-8290.CD-20-0116. View

16.

Zeng Z, Li J, Zhang J, Li Y, Liu X, Chen J . Immune and stromal scoring system associated with tumor microenvironment and prognosis: a gene-based multi-cancer analysis. J Transl Med. 2021; 19(1):330. PMC: 8336334. DOI: 10.1186/s12967-021-03002-1. View

17.

Chen J, Yang H, Teo A, Amer L, Sherbaf F, Tan C . Genomic landscape of lung adenocarcinoma in East Asians. Nat Genet. 2020; 52(2):177-186. DOI: 10.1038/s41588-019-0569-6. View

18.

Bie Y, Wang J, Xiong L, Wang D, Liao J, Zhang Y . Lung adenocarcinoma organoids harboring EGFR 19Del and L643V double mutations respond to osimertinib and gefitinib: A case report. Medicine (Baltimore). 2021; 100(11):e24793. PMC: 7982146. DOI: 10.1097/MD.0000000000024793. View

19.

Junttila M, de Sauvage F . Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013; 501(7467):346-54. DOI: 10.1038/nature12626. View

20.

Tanay A, Regev A . Scaling single-cell genomics from phenomenology to mechanism. Nature. 2017; 541(7637):331-338. PMC: 5438464. DOI: 10.1038/nature21350. View